High Quality Carbetocin Acetate 99% CAS NO (37025-55-1) for sale

1. Introduction to Carbetocin Acetate (37025-55-1):

Carbetocin acetate is a synthetic peptide analogue of oxytocin, a hormone involved in uterine contraction and lactation. Carbetocin acetate is primarily used in obstetrics and gynecology for the prevention of postpartum hemorrhage (PPH) following childbirth. With its uterotonic properties and prolonged duration of action, carbetocin acetate is an important medication for ensuring maternal safety during labor and delivery.

2. Chemical Composition and Molecular Structure:

Carbetocin acetate is derived from oxytocin through chemical modification, specifically acetylation and substitution of the cysteine residue at position 1 with a D-tryptophan moiety. This modification enhances the peptide's stability and pharmacokinetic properties, prolonging its duration of action compared to oxytocin. The molecular formula of carbetocin acetate is C45H69N11O12S2.

3. Mechanism of Action:

Carbetocin acetate acts as a selective agonist at oxytocin receptors located on uterine smooth muscle cells. By binding to these receptors, it stimulates uterine contractions and promotes the expulsion of the placenta following childbirth. Additionally, carbetocin acetate helps maintain uterine tone and reduce the risk of postpartum hemorrhage by enhancing uterine muscle contractility.

4. Prevention of Postpartum Hemorrhage:

Postpartum hemorrhage, characterized by excessive bleeding following childbirth, is a leading cause of maternal morbidity and mortality worldwide. Carbetocin acetate is administered prophylactically during the third stage of labor to reduce the risk of uterine atony and excessive bleeding. Its long-acting uterotonic effects provide sustained uterine contraction, minimizing the likelihood of PPH occurrence.

5. Clinical Efficacy and Safety:

Clinical trials and observational studies have demonstrated the efficacy and safety of carbetocin acetate in preventing postpartum hemorrhage and reducing the need for additional uterotonic agents or interventions. Its extended duration of action allows for a single-dose administration, simplifying dosing regimens and minimizing healthcare provider workload during labor and delivery.

6. Comparative Advantage over Oxytocin:

While oxytocin is commonly used for uterine stimulation during childbirth, carbetocin acetate offers several advantages, including a longer half-life, greater stability at room temperature, and reduced risk of side effects such as hypotension and tachycardia. These attributes make carbetocin acetate particularly suitable for settings where refrigeration and continuous monitoring may be limited.

7. Administration and Dosage:

Carbetocin acetate is typically administered intravenously as a single dose during the third stage of labor, immediately following the delivery of the baby. The recommended dosage varies depending on clinical guidelines and patient-specific factors but is generally lower than that of oxytocin due to its prolonged duration of action.

8. Safety Considerations:

While carbetocin acetate is generally well-tolerated, precautions should be taken to monitor maternal vital signs, uterine activity, and potential adverse reactions during and after administration. Common side effects may include nausea, vomiting, headache, and transient changes in blood pressure or heart rate. Rare but serious adverse events, such as uterine hypertonicity or rupture, may occur and require prompt medical intervention.

9. Regulatory Approval and Availability:

Carbetocin acetate has received regulatory approval in many countries for the prevention of postpartum hemorrhage and is included in clinical practice guidelines for obstetric care. It is available under various brand names and formulations, including injectable solutions and lyophilized powders for reconstitution, allowing for flexibility in dosing and administration.

10. Future Perspectives and Research Directions:

Continued research into the optimal use of carbetocin acetate, including dosage optimization, route of administration, and patient selection criteria, may further enhance its clinical utility and effectiveness in preventing postpartum hemorrhage. Additionally, ongoing pharmacovigilance efforts and post-marketing surveillance are essential for monitoring safety outcomes and ensuring the continued safe use of carbetocin acetate in obstetric practice.